Curriculum Vita

Catherine Cahill, PhD
Assistant Professor of Pediatrics

GENERAL INFORMATION

Name: Catherine Cahill

Office Address:

Massachusetts General Hospital,
Building 114, Room 3700,
16th Street,
Charlestown, MA 02129

E-mail: ccahill@helix.mgh.harvard.edu

Phone: 617-775-5524
Fax:

Place of Birth:

Education:

B. Positions and Honors.

Selected Awards

1985 Post graduate Scholarship for Training in Pure Science and Engineering,
Department of Education, Ireland
1987 Summer Research Bursary Equine Center Kildare, Ireland
1995 Honorarium/Seminar series University of California, Dan Diego
1996 Honorarium Seminar Series National Institutes of Health, NIA
2010 Paper of the Week ASBMB
2010 Front Cover Issue ASBMB
2010 Excellence in Tutoring Award Harvard Medical School

Service and Professional Activities

1999-2001 Part-time Curator Proteome Inc.

Committee Service

1992-1995 Dana Farber Cancer InstituteRadiation Safety Committee, Member
2011 Total Nutraceutical Solutions, Inc. Scientific Advisory Board, Member

Professional Societies

1987-1994 Society for Endocrinology, Member
1987-1995 Society for the Study of Fertility, Member
1990-present AAAS, Member
2008-present American Society for Biochemistry and Molecular Biology, ASBMB, Member

Grant Review Activities

2011 Reviewer, Ad hoc, Alzheimer’s Society

Editorial Activities:

2005- Ad hoc Reviewer, Hybridoma,International Journal of Clinical and Experimental Pathology.
2011- Editorial Board Member, World Journal of Biological Chemistry.

C. Selected peer-reviewed publications

http://connects.catalyst.harvard.edu/profiles/profile/person/87371

1. Cahill CM*, Van der Kolk H, Goode JA, Hayden TJ. Development of homologous radioimmunoassays for equine growth hormone and equine prolactin and their application to the detection of circulating levels of hormone in horse plasma. Reprod Nutr Dev. 1994; 34(4): 309-28. *corresponding author

2. Cahill CM, Waterman WR, Xie Y, Auron PE, Calderwood SK. Transcriptional repression of the prointerleukin 1beta gene by heat shock factor 1. J Biol Chem. 1996; 271(40): 24874-79.

3. Cahill CM, Lin HS, Price BD, Bruce JL, Calderwood SK. Potential role of heat shock transcription factor in the expression of inflammatory cytokines. Adv Exp Med Biol. 1997; 400B: 625-30.

4. Cahill CM*, Holder AT, Lawton TL, Butcher GW, Taussig MJ. Recognition of porcine growth hormone by a panel of monoclonal antibodies. Hybridoma. 1997; 16(4): 371-79. *corresponding author

5. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J Biol Chem. 1999; 274(10): 6421-31.

6. Housby JN, Cahill CM, Chu B, Prevelige R, Bickford K, Stevenson MA, Calderwood SK. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999; 11(5): 347-58.

7. Cahill CM*, Rogers JT. Anti-idiotypic sera against monoclonal anti-porcine growth hormone antibodies: production in rabbits and characterization of specificity. J Immunoassay. 1999; 20(1-2): 45-55. *corresponding author

8. Wang X, Cahill CM, Pieyro MA, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology. 1999; 140(10): 4904-7.

9. Nasrin N, Ogg S, Cahill CM, Biggs W, Nui S, Dore J, Calvo D, Shi Y, Ruvkun G, Alexander-Bridges MC. DAF-16 recruits the CREB-binding protein coactivator complex to the insulin-like growth factor binding protein 1 promoter in HepG2 cells. Proc Natl Acad Sci U S A. 2000; 97(19): 10412-17.

10. Cahill CM, Tzivion G, Nasrin N, Ogg S, Dore J, Ruvkun G, Alexander-Bridges M. Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14-3-3-dependent and 14-3-3-independent pathways. J Biol Chem. 2001; 276(16): 13402-10.

11. Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, Gullans SR. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J Mol Neurosci. 2002; 19(1-2): 77-82.

12. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002; 277(47): 45518-28.

13. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci. 2003; 20(3): 267-75.

14. Thomson AM, Cahill CM, Kassachau KD, Toth, I., Epis MR, Bridges KR, Leedman PJ, Rogers JT. The acute box cis-element in human H-ferritin mRNA 5'untranslated region is an unique translation enhancer that binds poly(C)-binding proteins. J Biol Chem. 2005; 280 (34): 30032-45)

15. Bandyopadhyay, S., Hartley, D., Cahill , CM., Lahiri, DK, Chattopadhyay N., and Rogers J. T. Interleukin-1a stimulates non-amyloidogenic pathway by a-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J. Neurosci Res. 2006; 84 (1): 106-18.

16. Cahill CM* and Rogers, J. T. IL-1 beta induction of IL-6 is mediated by a novel PI3- Kinase dependent AKT-/IkB kinase alpha pathway targeting AP-1. J. Biol Chem. (2008); 283, (38): 25900-25912. *corresponding author

17. Cho, H.H*, Cahill C. M*. Vanderburg C R, Scherzer C R, Wang B, Huang X and Rogers J.T. (2010). Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1 (J. Biol Chem, 2010; (285): 31217-31232 *equal contribution) Paper of the week, front cover issue, authors profiles in ASBMB.

18. Rogers JT, Mikkilineni S, Cantuti-Castelvetri I, Smith DH, Huang X, Bandyopadhyay S, Cahill CM, Maccecchini ML, Lahiri DK, Greig NH. The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transmission 2011; (118): 493-507.

19. Rogers, JT, Bush AL, Cho HH, Smith DH, Thompson AM, Friedlich AL, Lahiri DK, Leedman PJ, Huang X, Cahill CM. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs, riboregulation against neural oxidative damage in Alzheimer’s disease. Biochem Soc. Transactions (2008); 36 (6): 1282-7.
Book Chapters
20. Cahill CM, Lahiri, DK, Huang X and Rogers JT. Amyloid precursor protein and alpha synuclein translation, regulation by Iron and Inflammation. Biochem Biophys Acta. (2009); 1790 (7): 615-28.
*top 5 most downloaded BBA review for 2009.

21. Zhao W, Liu Y, Cahill CM, Yang W, Rogers JT and Huang X. The role of T cells in Osteoporosis, an update. Int. J. Clin Exp Pathol (2009); 2 (6): 544-52

22. Cahill C.M*, Rogers, J.T and Walker W. A. The role of Phosphatidylinositol 3 kinase signaling in intestinal inflammation. Journal of Signal Transduction (in press). *corresponding author

Research Support

Active
2010-2012 NICHD, R01HD012437 (Dr. Allan Walker, PI)-29 Supplement 1 (Cahill, PI) Title: Investigation of the role of TAK1 in the anti-inflammatory role of TGFb in the developing enterocyte.
Aims: TAK1 is a serine threonine kinase activated both by IL-1b and TGFb??. It ?is ?upstream
of AP-1 and NFkB activation. We are investigating if TAK-1 is activated in the
immature enterocyte by TGFb and/or IL-1b, together with its’ role in the neonatal intestine.
Role: Principal Investigator

Pending
2012 R21, (Dr. Jack Rogers, PI)
Title: Post transcriptional control of hemorrhagic iron damage.
Role: Co- investigator

2012 R01 (Dr. Jack Rogers, PI)
Title: Post transcriptional control of alpha-synuclein and iron homeostasis
Role: Co-Investigator

Completed
2009-2010 MJFOX, Novel Approaches to Drug Discovery (Dr. Jack Rogers, PI)
Title: Optimization of posiphen analogs and alpha synuclein translation blockers.
Aims: The goals were to characterize the optimal anti-alpha synclein analog posiphen as a SNCA 5’UTR translation blocker for Parkinson’s disease therapeutics.
Role, Co-Investigator